KVK Reaches Global Resolution of DOJ Litigation
26 Feb 2024
Patent Infringement
NEWTOWN, Pa., Feb. 26, 2024 /PRNewswire/ -- KVK Tech, Inc. ("KVK"), announced today that it has resolved all matters involving the U.S. Attorney's Office for the Eastern District of Pennsylvania (EDPA) and the Consumer Protection Branch of the Department of Justice, including US v . Vepuri, et al. The government charged KVK and its affiliate KVK Research with two misdemeanor counts of distributing adulterated drugs.
Continue Reading
Preview
Source: PRNewswire
KVK Tech Manufacturing Facility (Newtown, Pennsylvania)
To resolve these charges, KVK has agreed to enter into a Deferred Prosecution Agreement (DPA) with the government that will, among other things, require that company to operate with an independent compliance monitor for the next three years. Also, KVK Research has agreed to plead guilty to the two misdemeanor counts charged and to pay financial penalties.
After Research is sentenced and the DPA is entered, the DOJ has agreed to dismiss all charges against the two individual defendants Murty Vepuri and Ashvin Panchal.
"KVK looks forward to putting this litigation behind us. We will continue to focus on providing high-quality, affordable generic pharmaceuticals to the American public" said Anthony Tabasso, KVK's CEO. "KVK remains committed to maintaining the highest levels of integrity, and we look forward to continuing to work with all relevant stakeholders to uphold those standards."
About KVK
Founded in 2004, KVK has fast become a trusted leader in specialty pharmaceutical manufacturing. KVK is a leader in the development and manufacture of high-quality, FDA-approved medicines that address unmet patient needs. KVK takes pride in its ability to advance medical care and offer low-cost alternatives in response to today's healthcare challenges. The dedicated team is comprised of individuals with the technical, clinical and business expertise that is necessary for innovation that results in the development of a diverse range of life-changing medicines for patients of all socio-economic levels. Learn more at https://kvktech.com/
SOURCE KVK Tech, Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.